Alzheimer?s disease (AD) is a devastating neurodegenerative disorder that is characterized by progressive cognitive and functional impairment, and ultimately memory loss. Most cases of AD are late-onset and sporadic, with no evidence for a Mendelian pattern of inheritance, suggesting a significant role for environmental contributions to disease onset and/or progression. There are no validated treatments that slow, halt or reverse the symptoms of AD, and currently approved pharmacotherapies provide only modest and transient benefits. Further, many recent drug trials have failed to meet their endpoints of dissolving hallmark plaques in the AD brain or improving memory. The pathological consequences leading to AD are believed to involve accumulation of the amyloid-? peptide (A?) in neurons followed by the deposition of neurofibrillary tangles, which result in the onset of synaptic and neuronal dysfunction and neuronal death in specific brain regions. AD pathology is characterized by an inflammatory response in circulating immune cells and in the brain's resident immune cells, known as microglia. Intriguingly, it has recently been shown that the microbiome of AD patients differs from that of matched healthy controls, and that antibiotic treatment in mouse models impacts A? pathology and immune responses. Notably, the microbiome regulates numerous immune cell types throughout the body. Our laboratory has discovered specific bacterial molecules that prevent inflammation, identified receptors and signaling pathways in immune cells that mediate anti-inflammatory effects, and revealed how host-microbial interactions can ameliorate inflammatory conditions in several mouse models. These major advances have been funded by the parent R01 from NIDDK. This Administrative Supplement proposes to leverage our ground-breaking studies of specific gut microbial molecules with potent anti- inflammatory properties to test novel treatments for AD.
Specific Aim 1 will profile the mucosal immune response, in unprecedented detail, in two well-established mouse models of AD. Further, we will determine if experimental gut inflammation accelerates or exacerbates AD-like pathologies and symptoms in mice.
Specific aim 2 will focus on testing novel therapies for AD by suppressing inflammation with gut bacterial molecules that prevent and treat intestinal inflammation. The innovative hypothesis being tested is that mucosal inflammation contributes to AD-like pathologies and behaviors in mouse models, and activation of anti-inflammatory immune cells by gut bacteria ameliorates learning and memory deficits. Validation of this concept, and discovery of underling mechanisms of action, will de-risk further research into the gut-brain connection in AD, and advance the exciting possibility that harnessing the gut microbiome may lead to safe and effective therapeutic options for Alzheimer?s disease, one of the greatest medical concerns of current and future generations.

Public Health Relevance

Alzheimer?s disease (AD) affects over 5 million patients, families and their caregivers in the United States, and represents a looming medical and economic burden to society. Recent investigations have implicated a role for the immune system in AD. This project will leverage validated anti-inflammatory strategies that harness beneficial capacities of the gut microbiome to treat the core pathologies and symptoms in AD mouse models, with the long-term goal of developing safe and effective treatments for Alzheimer?s disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
3R01DK078938-09S1
Application #
10121503
Study Section
Program Officer
Perrin, Peter J
Project Start
2020-07-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
9
Fiscal Year
2020
Total Cost
Indirect Cost
Name
California Institute of Technology
Department
Type
Schools of Arts and Sciences
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Donaldson, G P; Ladinsky, M S; Yu, K B et al. (2018) Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360:795-800
Lee, Yun Kyung; Mehrabian, Parpi; Boyajian, Silva et al. (2018) The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer. mSphere 3:
Edelblum, Karen L; Sharon, Gil; Singh, Gurminder et al. (2017) The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability. Cell Mol Gastroenterol Hepatol 4:285-297
Meisel, Marlies; Mayassi, Toufic; Fehlner-Peach, Hannah et al. (2017) Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis. ISME J 11:15-30
Yoo, Bryan B; Mazmanian, Sarkis K (2017) The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. Immunity 46:910-926
Sharon, Gil; Sampson, Timothy R; Geschwind, Daniel H et al. (2016) The Central Nervous System and the Gut Microbiome. Cell 167:915-932
Donaldson, Gregory P; Lee, S Melanie; Mazmanian, Sarkis K (2016) Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 14:20-32
Chu, Hiutung; Khosravi, Arya; Kusumawardhani, Indah P et al. (2016) Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 352:1116-20
Yang, Yang; Wang, Chunlin; Yang, Qunying et al. (2015) Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. Elife 4:e09083
Yano, Jessica M; Yu, Kristie; Donaldson, Gregory P et al. (2015) Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161:264-76

Showing the most recent 10 out of 31 publications